Company intelligence / Profile preview

Pila Pharma

Malmö, Sweden

Ownership: Private
Employees: ~1
Development stage: Other

Overview

XEN-D0501, a TRPV1 antagonist, completed two Phase 2a trials showing good tolerability in type 2 diabetes patients, enhanced insulin response, and reduced ANP biomarker. Phase 2a dose-escalation trial (PP-CT03) planned for obesity/type 2 diabetes; orphan drug designation for erythromelalgia; preclinical POC for abdominal aorta aneurysm.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Uppsala University (Abdominal aorta aneurysm research)

Beyond the preview

Go deeper on Pila Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pila Pharma.

Explore the full profile